NASDAQ: RENB - Renovaro Biosciences Inc.

Altı ay boyunca karlılık: -84.31%
Sektör: Healthcare

Promosyon programı Renovaro Biosciences Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında

Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV.

Daha fazla ayrıntı
It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

EBITDA -0.0108
Число акций ао 0.05253 млрд
Цена ао 2.92
ISIN US29350E1047
Сайт https://www.renovarobio.com
EV/EBITDA 1.13
Валюта usd
IPO date 2015-02-02
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Günlük fiyat değişimi: -12.83% (0.5021)
Haftalık fiyat değişimi: -11.22% (0.493)
Aylık fiyat değişimi: -23.37% (0.5712)
3 ayda fiyat değişimi: -71.58% (1.54)
Altı ayda fiyat değişimi: -84.31% (2.79)
Yıllık fiyat değişimi: -90.48% (4.6)
3 yılda fiyat değişimi: -94.45% (7.88)
5 yılda fiyat değişimi: -90.71% (4.71)
Yılbaşından bu yana fiyat değişimi: -84.31% (2.79)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA -0.1909 0
Toplam: 2.5

Yeterlik

İsim Anlam Seviye
ROA, % -68.07 0
ROE, % -85.34 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.2871 10
Toplam: 8.6

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 42.56 6
karlılık Ebitda, % 80.4 9
karlılık EPS, % 5.46 1
Toplam: 5.4
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Vanguard Group Inc 390107 1.01
Morgan Stanley 362978 0.94
Geode Capital Management, LLC 362409 0.93
Blackrock Inc. 304656 0.79
Millennium Management LLC 126314 0.33
Susquehanna International Group, LLP 119459 0.31
State Street Corporation 97687 0.25
Northern Trust Corporation 88101 0.23
683 Capital Management LLC 73706 0.19
Qube Research & Technologies Ltd 67978 0.18

ETF Paylaşmak, % Yıllık karlılık, % Temettüler, %
ProShares Hedge Replication ETF 0.00016 5.9237999659878 1.47892
iShares Micro-Cap ETF 0.00641 36.318555985322 1.54048
iShares Russell 2000 Growth ETF 0.00112 38.042556988 0.6026
ProShares UltraPro Russell2000 0.00055 89.821266282945 1.47873
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 Growth ETF 0 39.350070246167 0.60264
Vanguard Russell 2000 ETF 0 35.648084105685 1.48801



Süpervizör İş unvanı Ödeme Doğum yılı
Dr. Francois Binette M.Sc., Ph.D. COO and Executive VP for Research & Development 504.38k 1964 (60 yıllar)
Dr. Serhat Gümrükcü Co-Founder & Inventor N/A
Mr. Greg Duczynski Ph.D. Senior Vice President for Clinical Operations N/A
Hon. Mark R. Dybul M.D. CEO, Director & Member of HBV Scientific Advisory Board 764.58k 1963 (61 yıl)
Mr. Simon Tarsh Interim Chief Financial Officer N/A 1961 (63 yıl)

Adres: United States, Los Angeles. CA, 2080 Century Park East - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.renovarobio.com